Aeterna Zentaris $AEZS signed an exclusive license agreement with Specialised Therapeutics Asia (STA) for the commercialization rights to Zoptrex (zoptarelin doxorubicin) in Australia and New Zealand. As per the terms of the agreement, Aeterna will get an upfront payment, milestones and double-digit royalties on net sales. STA will be responsible for the development, registration, reimbursement and commercialization of Zoptrex in those markets. Aeterna will supply the product for the duration of the contract. Zoptrex is currently in Phase 3 development for endometrial cancer. If all goes well, a New Drug Application (NDA) will be filed in the U.S. in H1 2017. It is in Phase 2 development for ovarian cancer and prostate cancer.
Celgene $CELG and Agios Pharmaceuticals $AGIO signed a partnership deal with Abbott $ABT to develop and commercialize companion diagnostic tests to identify isocitrate dehydrogenase (IDH) mutations in patients with acute myeloid leukemia (AML). The tests will be conducted on Abbott’s m2000 RealTime System, an automated polymerase chain reaction (PCR) instrument. Celgene is focusing on the development of IDH2 inhibitor, enasidenib, for the treatment of IDH2-positive AML. Agios is developing an IDH1 inhibitor, AG-120 for AML patients positive for that mutation.
RXi Pharmaceuticals $RXII signed an exclusive option agreement to acquire all outstanding capital stock of privately held Mirlmmune. As per the terms of the agreement, RXi would issue stock equal to 19.99% of its outstanding shares along with additional consideration tied to milestones. It can exercise the option until April 5, 2017. Mirlmmune is developing next-generation therapeutics in immune-oncology based in adoptive cell transfer. Both companies have existing relationship. Earlier in 2015, both signed an exclusive deal related to RXs’s self-delivering RNAi technology.
Biostar Pharmaceuticals $BSPM entered into a securities purchase agreement with certain institutional investors for the direct placement of 425K shares of common stock at $4.50 and 3.5-year warrants to purchase 212.5K shares of common at $5.55. The closing date is October 17. The proceeds will be utilized for working capital requirements and other corporate purposes.